• Clinical Cancer Research current issue ,
• The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

  Purpose:PARP inhibitors are approved for the treatment of high-grade serous ovarian cancers (HGSOC). Therapeutic resistance, resulting from restoration of homologous recombination (HR) repair or replication fork stabilization, is a pressing clinical problem. We assessed the activity of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor known to cause replication catastrophe, as monotherapy and in combination with the PARP inhibitor olaparib in p

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient

  A multitude of regulatory approvals has recently changed the therapeutic landscape of acute myeloid leukemia. Among these was upfront therapy with the Hedgehog inhibitor glasdegib with low-dose cytarabine. Understanding the process of and rationale for approval of this promising combination is timely and valuable for the oncology community. See related article by Norsworthy et al., p. 6021

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Impact of AAV2 and Hepatitis B Virus Integration Into Genome on Development of Hepatocellular Carcinoma in Patients with Prior Hepatitis B Virus Infection

  Purpose:Hepatitis B viral (HBV) DNA is frequently integrated into the genomes of hepatocellular carcinoma (HCC) in patients with chronic HBV infection (chronic HBV, hereafter), whereas the frequency of HBV integration in patients after the disappearance of HBV (prior HBV, hereafter) has yet to be determined. This study aimed to detect integration of HBV and adeno-associated virus type 2 (AAV2) into the human genome as a possible oncogenic event.

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Twist of Fate for Acute Promyelocytic Leukemia: TRIB3-TWIST1 Interaction Promotes Resistance

  While acute promyelocytic leukemia has a good prognosis with all-trans retinoic acid (ATRA) treatment, ATRA resistance is a major obstacle. It is now demonstrated that TRIBBLES 3 (TRIB3) stabilizes TWIST1, leading to ATRA resistance. Peptides that disrupt this interaction lead to the degradation of TWIST1 and overcome ATRA resistance. See related article by Lin et al., p. 6228

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma

  Purpose:Emerging evidence indicates that gut microbiome plays a crucial role in the cancer pathogenesis. Although Fusobacterium nucleatum (F. nucleatum) is associated with poor prognosis in multiple cancers, its clinical significance in predicting response to chemotherapy in patients with esophageal squamous cell carcinoma (ESCC) remains unclear. Experimental Design:The F. nucleatum levels were quantified by qPCR assays in tumor tissues from 551

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia

  On November 21, 2018, the FDA approved glasdegib (Daurismo; Pfizer), a small-molecule Hedgehog inhibitor, in combination with low-dose cytarabine (LDAC) for treatment of newly diagnosed acute myeloid leukemia (AML) in adults ≥ 75 years or with comorbidities that preclude use of intensive induction chemotherapy. Evidence of clinical benefit came from Study BRIGHT AML 1003, a randomized trial comparing glasdegib+LDAC with LDAC alone for treatment o

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Highlights of This Issue

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors

  Advances in diagnosis and treatment have resulted in a high rate of survival for many patients with early-stage cancers. However, identifying who is at ongoing risk of relapse remains of high priority to direct subsequent adjuvant therapy. Multiple recent retrospective studies have shown that detection of tumor-derived materials in blood, in particular with circulating tumor DNA (ctDNA) analysis, can identify patients with residual disease before

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model

  Purpose:Cholangiocarcinoma is a malignancy of bile duct with a poor prognosis. Conventional chemotherapy and radiotherapy are generally ineffective, and surgical resection is the only curative treatment for cholangiocarcinoma. L1-cell adhesion molecule (L1CAM) has been known as a novel prognostic marker and therapeutic target for cholangiocarcinoma. This study aimed to evaluate the feasibility of immuno-PET imaging–based radioimmunotherapy using

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation

  Purpose:Iododeoxyuridine (IUdR) is a potent radiosensitizer; however, its clinical utility is limited by dose-limiting systemic toxicities and the need for prolonged continuous infusion. 5-Iodo-2-pyrimidinone-2'-deoxyribose (IPdR) is an oral prodrug of IUdR that, compared with IUdR, is easier to administer and less toxic, with a more favorable therapeutic index in preclinical studies. Here, we report the clinical and pharmacologic results of a fi

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo

  Purpose:The goal of this study was to characterize the activity of the covalent CDK7 inhibitor THZ1 in multiple myeloma models. Experimental Design:Multiple myeloma lines were exposed to varying THZ1 concentrations alone or with carfilzomib or ABT-199, after which apoptosis was monitored by flow cytometry, protein expression by Western blot analysis, mRNA by RT-PCR. Analogous studies were performed in cells ectopically expressing c-MYC, MCL-1, o

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study

  Purpose:Combining anti-GD2 (disialoganglioside) mAb with GM-CSF, IL2, and isotretinoin is now FDA-approved for high-risk neuroblastoma minimal residual disease (MRD) therapy. The humanized anti-GD2 antibody conjugated to IL2 (hu14.18-IL2) has clinical activity in neuroblastoma and is more effective in neuroblastoma-bearing mice than antibody and cytokine given separately. We therefore evaluated the safety, tolerability, and antitumor activity of

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

  Purpose:Patient-derived xenograft (PDX) models accurately recapitulate the tumor of origin in terms of histopathology, genomic landscape, and therapeutic response, but some limitations due to costs associated with their maintenance and restricted amenability for large-scale screenings still exist. To overcome these issues, we established a platform of 2D cell lines (xeno-cell lines, XL), derived from PDXs of colorectal cancer with matched patient

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221

  Purpose:Monalizumab binds CD94/NKG2A, preventing HLA-E inhibition of tumor lymphocytes. A dose-ranging/cohort expansion trial of monalizumab for recurrent gynecologic malignancies was conducted to determine the recommended phase II dose (RP2D) and to explore clinical activity, pharmacokinetics, pharmacodynamics, safety, and immunogenicity. Patients and Methods:Participants (and part 2 expansion cohorts) included (i) platinum-sensitive ovarian, (

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations

  Purpose:Patients with SCLC rarely undergo biopsies at relapse. When pursued, tissue obtained can be inadequate for molecular testing, posing a challenge in identifying potentially targetable alterations in a clinically meaningful time frame. We examined the feasibility of circulating tumor DNA (ctDNA) testing in identifying potentially targetable alterations in SCLC. Experimental Design:ctDNA test results were prospectively collected from patien

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

  Purpose:Atezolizumab [anti–programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity. We evaluated the long-term safety and activity of atezolizumab, along with biological correlates of clinical activity endpoints, in a cohort of patients with melanoma in an ongoing phase Ia study (NCT01375842). Patients and Methods:Patients w

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin

  Purpose:Recent sequencing studies revealed that a subset of colorectal cancer harbors a significantly higher number of somatic mutations. These hypermutated tumors show distinct clinicopathologic features. However, the prognostic impact of the hypermutated tumors is not clearly established. Experimental Design:We analyzed tumor mutation burden (TMB) from targeted next-generation sequencing data of 40 major genes in 516 patients with colorectal c

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)

  Purpose:Bendamustine and rituximab (BR) has been established as a superior frontline therapy over R-CHOP in the treatment of follicular lymphoma (FL). Yttrium-90 Ibritumomab tiuxetan (90YIT) is an effective consolidation strategy after chemotherapy induction. This prospective, single-arm, multicenter, phase II trial evaluated the response rate, progression-free survival (PFS), and tolerability of BR followed by consolidation with 90YIT in patient

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer

  Purpose:Immune checkpoint inhibitors (ICI) are effective in only a minority of patients with esophagogastric cancer (EGC). Here, we aimed to identify predictors of durable clinical benefit to ICI in EGC. Experimental Design:Patients with advanced EGC treated with ICIs at Memorial Sloan Kettering Cancer Center (New York, NY) were identified. Clinicopathologic variables were assessed. In patients profiled by MSK-IMPACT–targeted sequencing, outcome

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN

  Purpose:Programmed death-ligand 1 (PD-L1) status by IHC is prognostic in metastatic renal cell carcinoma (mRCC), and its role as a potential predictive biomarker is under investigation. Using tumor tissue from the METEOR (NCT01865747) and CABOSUN (NCT01835158) clinical trials, we explored whether PD-L1 expression and the extent of the immune cell infiltrate can serve as prognostic and/or predictive biomarkers for cabozantinib and other targeted a

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Pik3ip1 Is a Negative Immune Regulator that Inhibits Antitumor T-Cell Immunity

  Purpose:Multiple negative regulators restrict the ability of T cells to attack tumors. This work demonstrates the role of PI3K-interacting protein 1 (Pik3ip1) in restraining T-cell responses and antitumor immunity. Experimental Design:An anti-Pik3ip1 mAb was generated to identify the Pik3ip1 expression pattern of hematopoietic cells. Pik3ip1–/– mice and a Pik3ip1 fusion protein were generated to investigate the effect of Pik3ip1 on T-cell–mediat

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study

  Purpose:Metastasis requires malignant cell circulation from the primary to a distant tissue. Elevated levels of circulating tumor cells (CTC) portend a poor prognosis in breast and other cancers. Recent studies have suggested that CTC clusters may be a factor in the metastatic process. We conducted a prospective retrospective study of the SWOG0500 clinical trial to test whether CTC clusters are associated with poorer prognosis. Experimental Desi

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib

  Purpose:Irinotecan and topotecan are used to treat a variety of different cancers. However, they have limitations, including chemical instability and severe side effects. To overcome these limitations, we developed the clinical indenoisoquinolines: LMP400 (indotecan), LMP776 (indimitecan), and LMP744. The purpose of the study is to build the molecular rationale for phase II clinical trials. Experimental Design:CellMinerCDB (http://discover.nci.n

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma

  Purpose:The use of VEGFR TKIs for the adjuvant treatment of renal cell carcinoma (RCC) remains controversial. We investigated the effects of adjuvant VEGFR TKIs on circulating cytokines in the ECOG-ACRIN 2805 (ASSURE) trial. Experimental Design:Patients with resected high-risk RCC were randomized to sunitinib, sorafenib, or placebo. Plasma from 413 patients was analyzed from post-nephrectomy baseline, 4 weeks, and 6 weeks after treatment initiat

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• TRIB3 Stabilizes High TWIST1 Expression to Promote Rapid APL Progression and ATRA Resistance

  Purpose:The resistance to differentiation therapy and early death caused by fatal bleeding endangers the health of a significant proportion of patients with acute promyelocytic leukemia (APL). This study aims to investigate the molecular mechanisms of all-trans retinoic acid (ATRA) resistance and uncover new potential therapeutic strategies to block the rapid progression of early death. Experimental Design:The important role of TWIST1 in APL leu

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

  Purpose:Molecular profiling has been used to select patients for targeted therapy and determine prognosis. Noninvasive strategies are critical to hepatocellular carcinoma (HCC) given the challenge of obtaining liver tissue biopsies. Experimental Design:We analyzed blood samples from 206 patients with HCC using comprehensive genomic testing (Guardant Health) of circulating tumor DNA (ctDNA). Results:A total of 153/206 (74.3%) were men; median ag

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• E{mu}-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma

  Purpose:Aberrant Myc expression is a major factor in the pathogenesis of aggressive lymphoma, and these lymphomas, while clinically heterogeneous, often are resistant to currently available treatments and have poor survival. Myc expression can also be seen in aggressive lymphomas that are observed in the context of CLL, and we sought to develop a mouse model that could be used to study therapeutic strategies for aggressive lymphoma in the context

  Clinical Cancer Research current issue

  Tue Oct 15, 2019 00:05
• Cortex
• Structural and functional brain correlates of Theory of Mind impairment post-stroke

  Publication date: Available online 14 October 2019Source: CortexAuthor(s): Juan F. Domínguez D, Zoie Nott, Kristina Horne, Tarran Prangley, Alexandra G. Adams, Julie D. Henry, Pascal MolenberghsAbstractThe ability to understand the mental states of others – also known as Theory of Mind (ToM) – is critical for normal social interactions. We combine behavioural probes with structural and functional brain imaging to provide the first comprehensive a

  Cortex

  Tue Oct 15, 2019 07:37
• Analytical Chemistry
• [ASAP] Highly Integrated Microfluidic Chip Coupled to Mass Spectrometry for Online Analysis of Residual Quinolones in Milk

  Analytical ChemistryDOI: 10.1021/acs.analchem.9b01844

  Analytical Chemistry

  Mon Oct 14, 2019 21:00
• [ASAP] Identification and Sequencing of N-Terminal Peptides in Proteins by LC-Fluorescence-MS/MS: An Approach to Replacement of the Edman Degradation

  Analytical ChemistryDOI: 10.1021/acs.analchem.9b02754

  Analytical Chemistry

  Mon Oct 14, 2019 21:00
• [ASAP] Ultrasensitive Apurinic/Apyrimidinic Site-Specific Ratio Fluorescent Rotor for Real-Time Highly Selective Evaluation of mtDNA Oxidative Damage in Living Cells

  Analytical ChemistryDOI: 10.1021/acs.analchem.9b03494

  Analytical Chemistry

  Mon Oct 14, 2019 21:00
• [ASAP] Isolation and Retrieval of Extracellular Vesicles for Liquid Biopsy of Malignant Ground-Glass Opacity

  Analytical ChemistryDOI: 10.1021/acs.analchem.9b03064

  Analytical Chemistry

  Mon Oct 14, 2019 21:00
• [ASAP] Dual-Monitoring Glycosylation and Local pH in Live Cells by Metabolic Oligosaccharide Engineering with a Ratiometric Fluorescent Tag

  Analytical ChemistryDOI: 10.1021/acs.analchem.9b03047

  Analytical Chemistry

  Mon Oct 14, 2019 21:00
• [ASAP] Anomalous Proton Transport across Silica Nanochannel Membranes Investigated by Ion Conductance Measurements

  Analytical ChemistryDOI: 10.1021/acs.analchem.9b01914

  Analytical Chemistry

  Mon Oct 14, 2019 21:00
• [ASAP] Imaging and Inhibiting: A Dual Function Molecular Flare for Cancer Cells

  Analytical ChemistryDOI: 10.1021/acs.analchem.9b02558

  Analytical Chemistry

  Mon Oct 14, 2019 21:00
• Journal of Evolutionary Biology
• Mating system drives the mate selection in aphidophagous ladybird, Menochilus sexmaculatus

  Abstract Mate competition and selection of mates is strongly influenced by the organism's mating system. Earlier it was considered the monogamous matings provide more benefits as compared to polygamous matings. However, later studies have proven that in polygamous system, females gain resources and, genetic benefits from the males, thereby indulging in multiple mating, leading males to access maximum females. In ladybird, Menochilus sexmaculatus

  Journal of Evolutionary Biology

  Mon Oct 14, 2019 12:55
• Attractive male sticklebacks carry more oxidative DNA damage in the soma and germline

  Abstract Trade‐offs between the expression of sexual signals and the maintenance of somatic and germline tissues are expected when these depend upon the same resources. Despite the importance of sperm DNA integrity, its trade‐off with sexual signalling has rarely been explored. We experimentally tested the trade‐off between carotenoid‐based sexual colouration and oxidative DNA damage in skeletal muscle, testis and sperm by manipulating reproduct

  Journal of Evolutionary Biology

  Mon Oct 14, 2019 10:55
• The cost and benefit of quorum sensing controlled bacteriocin production in Lactobacillus plantarum

  Abstract Bacteria eliminate competitors via ‘chemical warfare’ with bacteriocins. Some species appear to adjust bacteriocin production conditionally in response to the social environment. We tested whether variation in the cost and benefit of producing bacteriocins could explain such conditional behaviour, in the bacteria Lactobacillus plantarum. We found that: (1) bacterial bacteriocin production could be upregulated by either the addition of a

  Journal of Evolutionary Biology

  Mon Oct 14, 2019 01:13
• Brain size affects responsiveness in mating behavior to variation in predation pressure and sex‐ratio

  Abstract Despite ongoing advances in sexual selection theory, the evolution of mating decisions remains enigmatic. Cognitive processes often require simultaneous processing of multiple sources of information from environmental and social cues. However, little experimental data exist on how cognitive ability affects such fitness‐associated aspects of behavior. Using advanced tracking techniques, we studied mating behaviors of guppies artificially

  Journal of Evolutionary Biology

  Mon Oct 14, 2019 01:09
• Radiation Molecular Biology.
• Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non–small Cell Lung Cancer: A Phase II Randomized Trial

  Publication date: Available online 15 October 2019Source: International Journal of Radiation Oncology*Biology*PhysicsAuthor(s): Xin Shelley Wang, Qiuling Shi, Tito Mendoza, Steven Lin, Joe Y. Chang, Raza H. Bokhari, Hui-Kai Lin, Araceli Garcia-Gonzalez, Mona Kamal, Charles S. Cleeland, Zhongxing LiaoAbstractPurposeIn patients with non–small cell lung cancer (NSCLC), concurrent chemoradiation therapy (CRT) exacerbates a cluster of difficult-to-man

  Radiation Molecular Biology.

  Tue Oct 15, 2019 04:14
• Post-implant dosimetry of permanent prostate brachytherapy: comparison of MRI-only and CT-MRI fusion based workflows

  Publication date: Available online 15 October 2019Source: International Journal of Radiation Oncology*Biology*PhysicsAuthor(s): Reyhaneh Nosrati, Matthew Wronski, Chia-Lin Tseng, Hans Chung, Ana Pejović-Milić, Gerard Morton, Greg J. StaniszAbstractPurposeThe current MRI-CT fusion-based workflow for post-implant dosimetry of Low-Dose-Rate (LDR) prostate brachytherapy takes advantage of the superior soft tissue contrast of MRI but still relies on C

  Radiation Molecular Biology.

  Tue Oct 15, 2019 04:14
• SHORT-COURSE 2D-RADIOTHERAPY IN THE PALLIATIVE TREATMENT OF OESOPHAGEAL CANCER IN A DEVELOPING COUNTRY: A PHASE II STUDY (SHARON PROJECT)

  Publication date: Available online 14 October 2019Source: International Journal of Radiation Oncology*Biology*PhysicsAuthor(s): Biniyam Tefera Deressa, Wondemagegnehu Tigeneh, Netsanet Bogale, Milly Buwenge, Alessio G. Morganti, Eleonora FarinaAbstractPurposePatients with locally advanced and metastatic oesophageal cancer are usually affected by cancer-related symptoms which worsen their performance status and quality of life. The aim of this stu

  Radiation Molecular Biology.

  Tue Oct 15, 2019 04:14
• Royal Society of Chemistry (Great Britain) Society for Analytical Chemistry Society of Public Analysts (Great Britain)
• Epigenetic subtyping of white blood cells using a thermoplastic elastomer-based microfluidic emulsification device for multiplexed, methylation-specific digital droplet PCR

  Analyst, 2019, Accepted ManuscriptDOI: 10.1039/C9AN01316D, PaperLidija Malic, Jamal Daoud, Matthias Geissler, Alex Boutin, Ljuboje Lukic, Mojra Janta, Abdelrahman Elmanzalawy, Teodor VeresEpigenetic markers attract increasing attention for the study of phenotypic variations, which has led to the investigation of cell-lineage DNA methylation patterns that correlate with human leukocyte populations for obtaining...The content of this RSS Feed (c) T

  Royal Society of Chemistry (Great Britain) Society for Analytical Chemistry Society of Public Analysts (Great Britain)

  Mon Oct 14, 2019 16:00
• Feature Engineering Applied to Intraoperative In Vivo Raman Spectroscopy Sheds Light on Molecular Processes in Brain Cancer: A Retrospective Study of 65 Patients

  Analyst, 2019, Accepted ManuscriptDOI: 10.1039/C9AN01144G, CommunicationEmile Lemoine, Frédérick Dallaire, Rajeev Yadav, Rajeev Agarwal, Samuel Kadoury, Dominique Trudel, Marie-Christine Guiot, Kevin Petrecca, Frederic LeblondRaman Spectroscopy is a promising tool for neurosurgical guidance and cancer research. Quantitative analysis of Raman signal from living tissue is, however, limited. Their molecular composition is convoluted and influenced..

  Royal Society of Chemistry (Great Britain) Society for Analytical Chemistry Society of Public Analysts (Great Britain)

  Mon Oct 14, 2019 16:00
• Addressing the Practicalities of Anodic Stripping Voltammetry for Heavy Metal Detection: A Tutorial Review

  Analyst, 2019, Accepted ManuscriptDOI: 10.1039/C9AN01437C, Tutorial ReviewAlexandra Borrill, Nicole Elizabeth Reily, Julie V MacphersonAnodic Stripping Voltammetry (ASV) has the capability to detect heavy metals at sub ppb-level with portable and cheap instrumentation making it ideal for in the field (at the source) analysis,...The content of this RSS Feed (c) The Royal Society of Chemistry

  Royal Society of Chemistry (Great Britain) Society for Analytical Chemistry Society of Public Analysts (Great Britain)

  Mon Oct 14, 2019 16:00
• Cytokine Analysis at Countable Number of Molecules from Living Single Cell on Nanofluidic Device

  Analyst, 2019, Accepted ManuscriptDOI: 10.1039/C9AN01702J, PaperTatsuro Nakao, Yutaka Kazoe, Emi Mori, Kyojiro Morikawa, Takemichi Fukasawa, Ayumi Yoshizaki, Takehiko KitamoriAnalysis of proteins released from living single cell is strongly required in the fields of biology and medicine to elucidate the mechanism of gene expression, cell-cell communication and cytopathology. However,...The content of this RSS Feed (c) The Royal Society of Chemist

  Royal Society of Chemistry (Great Britain) Society for Analytical Chemistry Society of Public Analysts (Great Britain)

  Mon Oct 14, 2019 16:00
• Annals of Allergy, Asthma & Immunology
• From the Pages of Allergy Watch: January 2020

  For this ‘From the Pages of Allergy Watch’ reviews from several recent issues were selected which review articles about Allergic Skin Diseases, the focus of this issue of the Annals. The first article describes a unique minimally invasive method of skin tape stripping to identify infants with atopic dermatitis who are at increased risk for food allergy. The next study investigates the difference between IgE sensitivity and clinical reactivity to

  Annals of Allergy, Asthma & Immunology

  Mon Oct 14, 2019 17:00
• Benralizumab Efficacy for Patients with Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma

  Fixed airflow obstruction (FAO) is present for approximately 16% of patients with asthma, with a greater FAO incidence for patients with severe disease than for those with less severe disease.1,2 Patients with FAO have increased exacerbation frequency, decreased lung function, and greater mortality than patients without FAO.3,4 The risk of developing FAO is 2–4-fold greater for patients with increased sputum/blood eosinophil counts than for those

  Annals of Allergy, Asthma & Immunology

  Mon Oct 14, 2019 17:00
• The relationship between latitude and allergic gastroenteritis hospital admissions in New Zealand infants

  Recent epidemiological studies suggest that non-IgE-mediated childhood food allergic disorders such as eosinophilic esophagitis (EOE), celiac disease and allergic gastroenteritis (AG), may be increasing in parallel with previously observed increases in childhood IgE-mediated food allergy (FA) and food-induced anaphylaxis (FIA)1-4. The term AG encompasses food protein induced enterocolitis syndrome (FPIES), eosinophilic enteritis and colitis, food

  Annals of Allergy, Asthma & Immunology

  Mon Oct 14, 2019 17:00
• Cancer
• Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis

  British Journal of Cancer, Published online: 16 October 2019; doi:10.1038/s41416-019-0593-4Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis

  Cancer

  Tue Oct 15, 2019 17:00
• Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis

  Cancer

  Tue Oct 15, 2019 15:28